Navigation Links
Autism Consortium members publish in PNAS: Mechanism, treatment for Rett syndrome -- top cause autism girls
Date:2/9/2009

Autism Consortium Scientists Publish Study Defining Mechanism and Potential Treatment for Rett Syndrome, Leading Cause of Autism in Girls

- Clinical trial to test molecule in humans is being planned - - Data in PNAS reveals therapeutic that could apply to other forms of autism -

BOSTON JANUARY 9, 2009 The Autism Consortium, an innovative research, clinical and family collaboration dedicated to radically accelerating research and enhancing clinical care for autism spectrum disorders (ASDs), announced today that several Consortium members published a paper with significance for clinical trials in autism in the Proceedings of the National Academy of Sciences.

The research led by Autism Consortium members Mriganka Sur, PhD, Newton Professor of Neuroscience at the Picower Institute and Head of the MIT Department of Brain and Cognitive Sciences; and Rudolf Jaenisch, PhD, Founding Member, Whitehead Institute and Professor of Biology at MIT, demonstrates for the first time a mechanism for Rett Syndrome and a therapeutic that could be directly applicable to humans. As a result, a clinical trial in humans is in development.

IGF1 Reverses Rett Symptoms in Mice; Clinical Trial Planned

This groundbreaking study demonstrated that by treating mice with a peptide fragment of IGF1, a molecule that is utilized by the brain for neuronal and synaptic development, the symptoms of Rett Syndrome in the mice were largely reversed.

"The next step is to test recombinant human IGF1 which is already available for pediatric use in humans with the hope of treating or reversing Rett Syndrome," said Omar Khwaja, MD, PhD, Director of the Rett Syndrome Program at Children's Hospital Boston and head of the clinical trial team for IGF1. "We are working as quickly possible to develop the protocol, secure funding, and initiate the trial."

"This new study presents promising novel data suggesting that targeting the IGF1 signaling axis may present a useful therapeutic strategy that could ultimately be translated to humans," said Dr. Antony Horton, Chief Scientific Officer at the International Rett Syndrome Foundation. "We are encouraged by this collaboration between scientists and clinicians which is yielding valuable insights into potential new treatments for Rett syndrome."

About Rett Syndrome and the Findings

Rett Syndrome, a neurodevelopmental disorder mainly affecting girls and also the most common basis of autism in girls, is primarily caused by a sporadic mutation in the MECP2 gene on the X chromosome. The MECP2 gene makes a protein, also called MeCP2, believed to play a pivotal role in silencing, i.e. turning off the activity of other genes. The MECP2 mutation causes the regulatory mechanism to fail, which in turn causes other genes to function abnormally.

Rett is a genetic disorder of developmental arrest or failure of brain maturation. This is thought to occur when subsets of neurons and their connections (synapses) are disrupted during a very dynamic phase of brain development. Scientists have been investigating ways to reverse that arrest and therefore, turn brain activity back on.

By crossing into the brain and activating 'IGF1 signaling' IGF1 binds to its receptor and activates downstream molecules within neurons that make synapses mature. This activity in turn ends the developmental arrest thought to underlie the syndrome.

Using mutant mice in which MeCP2 is deleted, Sur and his co-authors demonstrated a major underlying mechanism for the disordersynapses in the brain remain immature and showed persistent, abnormal plasticity into adulthood.

"Our research is beginning to show that other forms of autism also have, as their basis, this persistent immaturity of synapses," said Sur. "As a result, an even more exciting and promising aspect of this work is the possibility that IGF1 or similar therapeutics could apply not only to autism caused by Rett Syndrome, but also to other causes of autism as well."


'/>"/>

Contact: Kathryn Morris
kathryn@kmorrispr.com
845-635-9828
Autism Consortium
Source:Eurekalert

Related medicine news :

1. Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism
2. 2 Genes Implicated in Autism
3. ToysRUs, Inc. Expands Its Support of Autism Speaks
4. Maximum Potential Offers Affordable Training Course for Parents of Children with Autism
5. New study explores the relationship between preterm birth and autism spectrum disorder
6. Upcoming Packard/Stanford Autism Symposium a Catalyst for Collaboration among Researchers and Community
7. Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County
8. Autism Speaks Announces Yearlong Partnership With Thomas & Friends (TM) Live! On Stage: A Circus Comes To Town
9. Federal Members of Advisory Committee Block Vaccine-Autism Research, Defy Wishes of Its Own Scientists, Autism Community, and Congress
10. Saliva Test Could Indicate Autism
11. Tampa is Latest Recipient of Project Lifesaver Grant Funds Through The National Autism Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Dawn ... is inaugurating a new charity drive to generate community support for efforts to educate ... into cures and treatments for all types of cancer. , Each day in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, ... communities in east Texas, is launching a regional charity effort to provide publicity ... 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning firm that serves residential and commercial clients in the greater Houston region, ... raise community support for the fight against cancer. , Founded by Tony and ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over ... in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for ... aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: